Table 3.

First-line Treatment of Invasive Aspergillosis: Prospective Controlled Trials

Study	N=	Design	Treatment	MDST (range)	Response (CR+PR)	Survival week 12
Herbrecht	277	op, rd	AmB Desoxycholate 1-1.5 mg/kg	10 (1-84)	31.6%	57.9%
2002 NEJM			Vori 2 × 6 mg/kg d1 and 2 × 4 mg/kg d2+ i.v.*	77 (2-84)	52.8%	70.8%
Cornely	201	db, rd	LAmB 3mg/kg (d1-14) } op3mg/kg d 15 +	14 (1-60)	50%	72%
2007 CID			LAmB 10 mg/kg (d1-14)	15 (1-57)	46%	59%
Herbrecht 2010 BMT **	24	op, sa	Caspofungin 70mg d1/50 mg d2+	24	33%	50%
Viscoli 2009JAC #	61	op, sa	Caspofungin 70mg d1/50 mg d 2+	15 (3-84)	33%	53%

Abbreviations: op = open, rd = randomized, db = double blind, sa = single arm, MDST = Median duration of study drug treatment in days, * a switch to oral voriconazole was allowed after day 7, **allogeneic cohort of patients, # hematological malignancies and autologous transplantation